2023
DOI: 10.1016/j.jpag.2022.10.007
|View full text |Cite
|
Sign up to set email alerts
|

Menstrual Suppression in Adolescent and Young Adult Transgender Males

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
6
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
5
1

Relationship

0
6

Authors

Journals

citations
Cited by 7 publications
(6 citation statements)
references
References 16 publications
0
6
0
Order By: Relevance
“…11 Another recent study explored bleeding patterns among 220 TGD adolescents starting testosterone gender-affirming hormone, gonadotropinreleasing hormone analogue, hormonal treatment for menstrual suppression, or a combination of these. 12 They showed that amenorrhea was achieved most rapidly using gonadotropin-releasing hormone analogue and norethindrone acetate (77 and 78 days, respectively) compared with testosterone (151 days) and IM medroxyprogesterone (182 days). 12 Improving gender dysphoria was reported as the most common indication for menstrual suppression among individuals already on this treatment in our study.…”
Section: Discussionmentioning
confidence: 99%
See 3 more Smart Citations
“…11 Another recent study explored bleeding patterns among 220 TGD adolescents starting testosterone gender-affirming hormone, gonadotropinreleasing hormone analogue, hormonal treatment for menstrual suppression, or a combination of these. 12 They showed that amenorrhea was achieved most rapidly using gonadotropin-releasing hormone analogue and norethindrone acetate (77 and 78 days, respectively) compared with testosterone (151 days) and IM medroxyprogesterone (182 days). 12 Improving gender dysphoria was reported as the most common indication for menstrual suppression among individuals already on this treatment in our study.…”
Section: Discussionmentioning
confidence: 99%
“…12 They showed that amenorrhea was achieved most rapidly using gonadotropin-releasing hormone analogue and norethindrone acetate (77 and 78 days, respectively) compared with testosterone (151 days) and IM medroxyprogesterone (182 days). 12 Improving gender dysphoria was reported as the most common indication for menstrual suppression among individuals already on this treatment in our study. This desire to suppress periods may be due to the fact that menstruation is considered a feminine trait.…”
Section: Discussionmentioning
confidence: 99%
See 2 more Smart Citations
“…11 The experience of gender incongruity or dysphoria is another welldocumented source of barriers to health equity, including the lack of access to appropriate contraceptive, menstrual, pregnancy-related, and general medical care. 5,[12][13][14][15][16][17][18][19][20] For this reason, a shared decision-making (SDM) model is essential for providing menstrual healthcare to TGD AYA. SDM frames the patient as the expert in their own needs and the healthcare provider as an expert guide in helping the patient decide which specific interventions best match the patients' desires.…”
Section: Shared Decision-making Framework and Equitymentioning
confidence: 99%